Building efficient comparative effectiveness trials through adaptive designs, utility functions, and accrual rate optimization: finding the sweet spot

Statistics in Medicine

Volumn 34, Issue 7, 2015, Pages 1134-1149

  Gajewski, Byron J ^a   Berry, Scott M ^b   Quintana, Melanie ^b   Pasnoor, Mamatha ^a   Dimachkie, Mazen ^a   Herbelin, Laura ^a   Barohn, Richard ^a  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^b BERRY CONSULTANTS   (United States)

Author keywords

accrual; Bayesian adaptive design; comparative effectiveness; group sequential monitoring; patient centered outcomes

Indexed keywords

ACCRUAL RATE; ACCRUAL RATE OPTIMIZATION; ALGORITHM; ARTICLE; BAYESIAN ADAPTIVE DESIGN; COMPARATIVE EFFECTIVENESS TRIAL; COMPARATIVE STUDY; COMPUTER SIMULATION; CRYPTOGENIC SENSORY POLYNEUROPATHY; DRUG DEVELOPMENT; EXPECTED COST; EXPECTED TRIAL DURATION; GROUP SEQUENTIAL MONITORING; METHODOLOGY; MONITORING; PARAMETERS; PATIENT PREFERENCE; POISSON DISTRIBUTION; POLYNEUROPATHY; PROBABILITY; PROCESS OPTIMIZATION; RANDOMIZATION; RESPONSE ADAPTIVE RANDOMIZATION; SAMPLE SIZE; STATISTICAL PARAMETERS; STUDY DESIGN; SWEET SPOT ALGORITHM; UTILITY FUNCTION;

EID: 85006371381     PISSN: 02776715     EISSN: 10970258     Source Type: Journal    
DOI: 10.1002/sim.6403     Document Type: Article

References (22)

1. Chevret S, Bayesian adaptive clinical trials: a dream for statisticians only? Statistics in Medicine 2012; 31:1002–1013.
2. Berry DA, A guide to drug discovery: Bayesian clinical trials (2006), Nature Reviews Drug Discovery 2006; 5(1): 27–36.
3. Berry DA, Adaptive clinical trials in oncology, Nature Reviews Clinical Oncology 2012; 9(4): 199–207.
4. Lee JJ, Chu CT, Bayesian clinical trials in action, Statistics in Medicine 2012; 31(25): 2955–2972.
5. Bonangelino P, Irony T, Liang S, Li X, Mukhi V, Ruan S, Xu Y, Yang X, Wang C, Bayesian approaches in medical device clinical trials: a discussion with examples in the regulatory setting, Journal of Biopharmaceutical Statistics 2011; 21(5): 938–953.
6. Biswas S, Liu DD, Lee JJ, Berry DA, Bayesian clinical trials at the University of Texas M. D. Anderson Cancer Center, Clinical Trials 2009; 6(3): 205–216.
7. Berry SM, Carlin BP, Lee JJ, Muller P. Bayesian Adaptive Methods for Clinical Trials, CRC Press: New York, 2011.
8. Patient Centered Outcomes Research Institute (PCORI), PCORI methodology standards, 2012. (Available from: http://www.pcori.org/assets/PCORI-Methodology-Standards.pdf) (Accessed on 13 August 2014).
9. Connor JT, Elm JJ, Broglio KR, ADAPT-IT Investigators, Bayesian adaptive trials offer advantages in comparative effectiveness trials: an example in status epilepticus, Journal of Clinical Epidemiology 2013; 66(8S): S130–137.
10. Berry SM, Spinelli W, Littman GS, Liang JZ, Fardipour P, Berry DA, Lewis RL, Krams M, A Bayesian dose-finding trial with adaptive dose expansion to flexibly assess efficacy and safety of an investigational drug, Clinical Trials 2010; 7:121–135.
11. Stallard N, Thall PF, Whitehead J, Decision theoretic designs for phase II clinical trials with multiple outcomes, Biometrics 1999; 55:971–977.
12. Thall PF, Cook JD, Dose-finding based on efficacy-toxicity trade-offs, Biometrics 2004; 60:684–693.
13. Rossell D, Müller P, Rosner GL, Screening designs for drug development, Biostatistics 2007; 8:595–608.
14. Anisimov VV, Fedorov VV, Modelling prediction and adaptive adjustment of recruitment in multicentre trials, Statistics in Medicine 2007; 26(27): 4958–4975.
15. Gajewski BJ, Simon SD, Carlson SE, Predicting accrual in clinical trials with Bayesian posterior predictive distributions, Statistics in Medicine 2008; 27(13): 2328–2340.
16. Zhang X, Long Q, Stochastic modeling and prediction for accrual in clinical trials, Statistics in Medicine 2010; 29:649–658.
17. Anisimov VV, Effects of unstratified and centre-stratified randomization in multi-centre clinical trials, Pharmaceutical Statistics 2011; 10:50–59.
18. Gajewski BJ, Simon SD, Carslon SE, On the existence of constant accrual rates in clinical trials and direction for future research, International Journal of Statistics and Probability 2012; 1(2): 43–46.
19. Kawasaki Y, Miyaoka E, A Bayesian inference of P(π1 > π2) for two proportions, Journal of Biopharmaceutical Statistics 2012; 22:425–437.
20. Pasnoor M, Dimachkie MM, Barohn RJ, Cryptogenic sensory polyneuropathy, Neurologic Clinics 2013; 31:463–476.
21. Jennison C, Turnbull BW. Group Sequential Methods with Applications to Clinical Trials, Chapman & Hall/CRS: New York, 2000.
22. Breau RH, Carnat TA, Gaboury I, Inadequate statistical power of negative clinical trials in urological literature, Journal of Urology 2006; 176(1): 263–266.